Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Polypid Ltd (PYPD)

Polypid Ltd (PYPD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,513
  • Shares Outstanding, K 4,797
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,870 K
  • 60-Month Beta 1.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PYPD with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.96
  • Number of Estimates 1
  • High Estimate -1.96
  • Low Estimate -1.96
  • Prior Year -8.41
  • Growth Rate Est. (year over year) +76.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.20 +8.50%
on 04/08/24
5.50 -17.14%
on 03/28/24
-0.14 (-3.04%)
since 03/22/24
3-Month
4.20 +8.50%
on 04/08/24
7.00 -34.90%
on 02/14/24
-2.07 (-31.21%)
since 01/24/24
52-Week
3.57 +27.81%
on 10/06/23
13.50 -66.24%
on 04/28/23
-8.94 (-66.24%)
since 04/24/23

Most Recent Stories

More News
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus...

PYPD : 4.56 (+1.62%)
PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022

PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...

PYPD : 4.56 (+1.62%)
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium...

PYPD : 4.56 (+1.62%)
PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections

PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming...

PYPD : 4.56 (+1.62%)
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of...

PYPD : 4.56 (+1.62%)
Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 289%: Read This Before Placing a Bet

The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 288.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

PYPD : 4.56 (+1.62%)
PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

•  Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently •  Recruitment...

PYPD : 4.56 (+1.62%)
PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA,...

PYPD : 4.56 (+1.62%)
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

• FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up•...

PYPD : 4.56 (+1.62%)
PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical...

PYPD : 4.56 (+1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PolyPid Ltd. is a pharmaceutical company. It discovers, develops and commercializes antibiotic drugs for the prevention of surgical infections. The company's product candidate includes D-PLEX100, BONYPID-1000 and BONYPID-500 which are in clinical stage. PolyPid Ltd. is based in Petach Tikva, Israel.

See More

Key Turning Points

3rd Resistance Point 4.61
2nd Resistance Point 4.60
1st Resistance Point 4.58
Last Price 4.56
1st Support Level 4.55
2nd Support Level 4.54
3rd Support Level 4.51

See More

52-Week High 13.50
Fibonacci 61.8% 9.71
Fibonacci 50% 8.53
Fibonacci 38.2% 7.36
Last Price 4.56
52-Week Low 3.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar